Sugi Predict

Sugi Predict / Compounds / SCHEMBL273986

SCHEMBL273986

SCHEMBL273986

CC(C)(C)OC(=O)N(N)c1ccc(F)cc1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MEN1 O00255 2/20 0.39
▸ KMT2A Q03164 2/20 0.39
▸ MT-CO2 P00403 1/20 0.38
▸ KCNQ4 P56696 3/20 0.38
▸ KCNQ5 Q9NR82 3/20 0.38
▸ GRM2 Q14416 1/20 0.37
▸ APP P05067 1/20 0.36
▸ KCNN4 O15554 1/20 0.35
▸ PAX8 Q06710 1/20 0.34
▸ KDM1A O60341 2/20 0.34
▸ HDAC8 Q9BY41 1/20 0.34
▸ HDAC6 Q9UBN7 1/20 0.34
▸ RIPK1 Q13546 2/20 0.33
▸ CTSS P25774 1/20 0.33
▸ CTSK P43235 1/20 0.33
▸ NPC1 O15118 1/20 0.33
▸ MAPT P10636 1/20 0.33
▸ XBP1 P17861 1/20 0.33
▸ MAPK1 P28482 1/20 0.33
▸ HTT P42858 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2529611 0.91 MT-CO2 (0.42) MT-CO2PAX8KDM1AHDAC6NPC1
SCHEMBL3410365 0.84 MT-CO2 (0.39) KMT2AMT-CO2PAX8MAPTRAB9A
SCHEMBL977449 0.84 ALDH1A1 (0.42) MEN1KMT2AMT-CO2PAX8NPC1
SCHEMBL272401 0.83 KIF11 (0.40) MT-CO2APPMAPTHTT
SCHEMBL3765238 0.83 GRM2 (0.33) MT-CO2KCNQ4KCNQ5GRM2HDAC8
SCHEMBL551649 0.83 MT-CO2 (0.53) MEN1KMT2AMT-CO2MAPTSMN1; SMN2
SCHEMBL14740797 0.83 RAB9A (0.41) MEN1KMT2AMT-CO2PAX8CTSS
SCHEMBL14740850 0.83 MT-CO2 (0.38) MT-CO2APPPAX8NPC1MAPT
SCHEMBL2354804 0.82 L3MBTL1 (0.43) MEN1KMT2APAX8MAPTRAB9A
SCHEMBL246278 0.81 CA1 (0.42) MEN1KMT2AMT-CO2NPC1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 45 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2751095-B1 NOVEL BENZODIAZEPINONES AS MODULATORS OF METABOTROPIC GLUTAMATE RECEPTOR FUNCTIONS AND NEUROLOGICAL USES THEREOF SANFORD BURNHAM MED RES INST (US) 2021-10-27 — — EP disclosed
US-10919851-B2 2-pyrrolidine phenylhydrazides antibacterial agents ABAC Therapeutics, S.L. (ES) 2021-02-16 — — US disclosed
US-10919851-B2 2-pyrrolidine phenylhydrazides antibacterial agents ABAC Therapeutics, S.L. (ES) 2021-02-16 — — US disclosed
EP-3490984-B1 2-PYRROLIDINE PHENYLHYDRAZIDES ANTIBACTERIAL AGENTS Abac Therapeutics Sl (ES) 2020-09-09 — — EP disclosed
EP-3490984-B1 2-PYRROLIDINE PHENYLHYDRAZIDES ANTIBACTERIAL AGENTS Abac Therapeutics Sl (ES) 2020-09-09 — — EP disclosed
CN-105683166-B Substituted pyrimidine Bmi-1 inhibitors PTC医疗公司 2020-06-16 — — CN disclosed
EP-3039015-B1 SUBSTITUTED PYRIMIDINE BMI-1 INHIBITORS PTC THERAPEUTICS INC (US) 2019-10-30 — — EP disclosed
US-10370371-B2 Substituted pyrimidine Bmi-1 inhibitors PTC THERAPEUTICS, INC. (US) 2019-08-06 — — US disclosed
US-20190177272-A1 2-PYRROLIDINE PHENYLHYDRAZIDES ANTIBACTERIAL AGENTS ABAC Therapeutics, S.L. (ES) 2019-06-13 — — US disclosed
US-20190177272-A1 2-PYRROLIDINE PHENYLHYDRAZIDES ANTIBACTERIAL AGENTS ABAC Therapeutics, S.L. (ES) 2019-06-13 — — US disclosed
US-7884109-B2 immunosuppressants such as 2-(6-Fluoro-1H-benzo[d]imidazol-1-yl)-9-((1R,4R)-4-hydroxy-1,2,3,4-tetrahydronaphthalen-1-yl)-7H-purin-8(9H)-one, used for the prevention and treatment of autoimmune diseases, inflammatory disease, mast cell mediated disease and transplant rejection WYETH LLC (US) 2011-02-08 — — US disclosed
WO-2010144371-A1 ALKANOYLAMINO BENZAMIDE ANILINE HDAC INIHIBITOR COMPOUNDS GILEAD COLORADO, INC. (US) 2010-12-16 — — WO disclosed
US-20100310500-A1 ALKANOYLAMINO BENZAMIDE ANILINE HDAC INHIBITOR COMPOUNDS GILEAD SCIENCES, INC. (US) 2010-12-09 — — US disclosed
WO-2010075542-A1 CDK INHIBITORS CURIS, INC. (US) 2010-07-01 — — WO disclosed
WO-2010009139-A2 IMIDAZOLYL PYRIMIDINE INHIBITOR COMPOUNDS GILEAD COLORADO, INC. (US) 2010-01-21 — — WO disclosed
US-20100009990-A1 IMIDAZOLYL PYRIMIDINE INHIBITOR COMPOUNDS GILEAD SCIENCES, INC. 2010-01-14 — — US disclosed
WO-2009048474-A1 2,7,9-SUBSTITUTED PURINONE DERIVATIVES FOR IMMUNOSUPPRESSION PHARMACOPEIA, INC. (US) 2009-04-16 — — WO disclosed
US-20080287468-A1 PURINE AND IMIDAZOPYRIDINE DERIVATIVES FOR IMMUNOSUPPRESSION PHARMACOPEIA, INC. (US) 2008-11-20 — — US disclosed
EP-1474416-A1 DIHYDROBENZODIAZEPIN-2-ONE-DERIVATIVES FOR THE TREATMENT OF NEUROLOGICAL DISORDERS F. HOFFMANN-LA ROCHE AG (CH) 2004-11-10 — — EP disclosed
WO-2003066623-A1 DIHYDROBENZODIAZEPIN-2-ONE DERIVATIVES FOR THE TREATMENT OF NEUROLOGICAL DISORDERS F. HOFFMANN-LA ROCHE AG (CH) 2003-08-14 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190177272-A1 2-PYRROLIDINE PHENYLHYDRAZIDES ANTIBACTERIAL AGENTS ATAD2, ATAD2B, ATAD5 MEN1 4779/4885KMT2A 2204/4885MT-CO2 1770/4885
US-20100009990-A1 IMIDAZOLYL PYRIMIDINE INHIBITOR COMPOUNDS HDAC1, CDK9, CDK2 MEN1 3550/4885KMT2A 279/4885MT-CO2 3554/4885
US-10370371-B2 Substituted pyrimidine Bmi-1 inhibitors BMI1, BAZ2A, BRPF3 MEN1 1305/4885KMT2A 121/4885MT-CO2 4529/4885
US-20100310500-A1 ALKANOYLAMINO BENZAMIDE ANILINE HDAC INHIBITOR COMPOUNDS HDAC1, HDAC5, HDAC7 MEN1 3816/4885KMT2A 47/4885MT-CO2 4252/4885
US-10919851-B2 2-pyrrolidine phenylhydrazides antibacterial agents ATAD2, ATAD2B, ATAD5 MEN1 4779/4885KMT2A 2204/4885MT-CO2 1770/4885
US-20080287468-A1 PURINE AND IMIDAZOPYRIDINE DERIVATIVES FOR IMMUNOSUPPRESSION TPMT, P2RY4, P2RY1 MEN1 3432/4885KMT2A 2848/4885MT-CO2 4067/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.